Search Results

Future destinations: how people cured of hepatitis C using direct acting antiviral drugs progress in a new HCV-free world. A thematic analysis.

• Authors : Donaldson, Sarah R.^1,2 (AUTHOR) ; Radley, Andrew^1,2 (AUTHOR); Dillon, John F.^1,2 (AUTHOR)

• Source: Harm Reduction Journal. 1/16/2025, Vol. 22 Issue 1, p1-12. 12p.

Record details

Antiviral treatment for viral pneumonia: current drugs and natural compounds.

• Authors : Zhang H; Institute of Medical Artificial Intelligence, Binzhou Medical University, Yantai, 264003, China.; Ge C

Subjects: Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/therapeutic use ; Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/pharmacology ; Pneumonia, Viral*/Pneumonia, Viral*/Pneumonia, Viral*/drug therapy

• Source: Virology journal [Virol J] 2025 Mar 06; Vol. 22 (1), pp. 62. Date of Electronic Publication: 2025 Mar 06.Publisher: BioMed Central Country of Publication: England NLM ID: 101231645 Publication Model: Electronic Cited Medium:

Record details

Fc-binding nanodisc restores antiviral efficacy of antibodies with reduced neutralizing effects against evolving SARS-CoV-2 variants.

• Authors : Hwang J; Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Sungkyunkwan University, Suwon, 16419, Republic of Korea.; Choi S

Subjects: SARS-CoV-2*/SARS-CoV-2*/SARS-CoV-2*/drug effects ; SARS-CoV-2*/SARS-CoV-2*/SARS-CoV-2*/immunology ; Antibodies, Neutralizing*/Antibodies, Neutralizing*/Antibodies, Neutralizing*/immunology SARS-CoV-2 variants

• Source: Journal of nanobiotechnology [J Nanobiotechnology] 2025 Jan 24; Vol. 23 (1), pp. 44. Date of Electronic Publication: 2025 Jan 24.Publisher: BioMed Central Country of Publication: England NLM ID: 101152208 Publication Model: Electronic Cited Medium:

Record details

Impact of hepatic steatosis on the efficacy of antiviral treatment for chronic hepatitis B and the establishment of predictive model: a cohort study.

• Authors : Ren G; Department of Infectious Disease, Liver Disease Center of Integrated Traditional Chinese and Western Medicine, The First Affiliated Hospital of Dalian Medical University, No. 222 Zhongshan Road, Xigang District, Dalian, 116000, Liaoning Province, China.; Jia K

Subjects: Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/therapeutic use ; Hepatitis B, Chronic*/Hepatitis B, Chronic*/Hepatitis B, Chronic*/drug therapy ; Hepatitis B, Chronic*/Hepatitis B, Chronic*/Hepatitis B, Chronic*/complications

• Source: Virology journal [Virol J] 2025 Feb 07; Vol. 22 (1), pp. 30. Date of Electronic Publication: 2025 Feb 07.Publisher: BioMed Central Country of Publication: England NLM ID: 101231645 Publication Model: Electronic Cited Medium:

Record details

Advances in antiviral strategies targeting mosquito-borne viruses: cellular, viral, and immune-related approaches.

• Authors : Khan A; Department of Biomedical Sciences and Institute for Medical Science, Jeonbuk National University Medical School, Jeonju, 54907, South Korea.; Zakirullah

Subjects: Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/pharmacology ; Mosquito Vectors*/Mosquito Vectors*/Mosquito Vectors*/virology; Animals

• Source: Virology journal [Virol J] 2025 Feb 04; Vol. 22 (1), pp. 26. Date of Electronic Publication: 2025 Feb 04.Publisher: BioMed Central Country of Publication: England NLM ID: 101231645 Publication Model: Electronic Cited Medium:

Record details

"I definitely cannot afford to be feeling poorly if there's no need to be": a qualitative evaluation of antiviral uptake following suspected occupational exposure to avian influenza.

• Authors : Pae R; South West Health Protection Team, UK Health Security Agency, Bristol, UK. .; Behavioural Science and Insights Unit, UK Health Security Agency, London, UK. .

Subjects: Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/therapeutic use ; Occupational Exposure*/Occupational Exposure*/Occupational Exposure*/prevention & control ; Influenza, Human*/Influenza, Human*/Influenza, Human*/prevention & control

• Source: BMC public health [BMC Public Health] 2025 Feb 02; Vol. 25 (1), pp. 421. Date of Electronic Publication: 2025 Feb 02.Publisher: BioMed Central Country of Publication: England NLM ID: 100968562 Publication Model: Electronic Cited Medium:

Record details

Impact of antiviral prophylaxis on EBV viremia and posttransplant lymphoproliferative disorders in solid organ transplant recipients: a systematic review and meta-analysis.

• Authors : Moghadamnia M; Department of Pharmacotherapy, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran.; Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Subjects: Lymphoproliferative Disorders*/Lymphoproliferative Disorders*/Lymphoproliferative Disorders*/prevention & control ; Lymphoproliferative Disorders*/Lymphoproliferative Disorders*/Lymphoproliferative Disorders*/etiology ; Lymphoproliferative Disorders*/Lymphoproliferative Disorders*/Lymphoproliferative Disorders*/epidemiology

• Source: Virology journal [Virol J] 2025 Jan 15; Vol. 22 (1), pp. 11. Date of Electronic Publication: 2025 Jan 15.Publisher: BioMed Central Country of Publication: England NLM ID: 101231645 Publication Model: Electronic Cited Medium:

Record details

Antiviral activity of silver nanoparticles against H1N1 influenza virus.

• Authors : Seyfi M; Department of Bacteriology & Virology, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, Iran.; Letafati A

Subjects: Influenza A Virus, H1N1 Subtype*/Influenza A Virus, H1N1 Subtype*/Influenza A Virus, H1N1 Subtype*/drug effects ; Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/pharmacology ; Silver*/Silver*/Silver*/pharmacology

• Source: BMC research notes [BMC Res Notes] 2025 Feb 18; Vol. 18 (1), pp. 75. Date of Electronic Publication: 2025 Feb 18.Publisher: Biomed Central Country of Publication: England NLM ID: 101462768 Publication Model: Electronic Cited Medium:

Record details

Safety, pharmacokinetics, and antiviral efficacy of the novel capsid assembly modulator GST-HG141 in patients with chronic hepatitis B: a phase 1 trial with a randomized, placebo-controlled design.

• Authors : Wu M; Phase I Clinical Trial Unit, First Hospital, Jilin University, Jilin, China.; Mai J

Subjects: Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/pharmacokinetics ; Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/adverse effects ; Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/therapeutic use

• Source: Virology journal [Virol J] 2024 Dec 20; Vol. 21 (1), pp. 328. Date of Electronic Publication: 2024 Dec 20.Publisher: BioMed Central Country of Publication: England NLM ID: 101231645 Publication Model: Electronic Cited Medium:

Record details

Changes in the expression profile of serum lncRNAs in pregnant women with high hepatitis B viral load during antiviral and non-antiviral treatment.

• Authors : Wang C; Department of Obstetrics and Gynecology, The People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning, China. .; Department of Obstetrics and Gynecology, People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, No. 6, Taoyuan Road, Qingxiu District, Nanning, China. .

Subjects: RNA, Long Noncoding*/RNA, Long Noncoding*/RNA, Long Noncoding*/blood ; Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/therapeutic use ; Viral Load*

• Source: BMC pregnancy and childbirth [BMC Pregnancy Childbirth] 2024 Oct 24; Vol. 24 (1), pp. 696. Date of Electronic Publication: 2024 Oct 24.Publisher: BioMed Central Country of Publication: England NLM ID: 100967799 Publication Model: Electronic Cited Medium:

Record details